Latest Director Participation News

Nyrada Inc. has secured ethics approval to launch a Phase IIa clinical trial for its heart attack drug Xolatryp®, with patient recruitment set for March 2026. The company maintains a solid cash position of AU$7.12 million as it expands its research into oncology.

Critica Limited has successfully closed the second tranche of its $8 million placement, issuing over 92 million shares and options to accelerate development at its Jupiter Rare Earth Project.

Dreadnought Resources reports a 36% increase in high-grade gold resources at Star of Mangaroon, secures $18 million in funding, and advances critical metals projects with promising drilling results and strategic partnerships.

Terrain Minerals has restarted its reverse circulation drilling campaign at the Smokebush Gold & Silver Project in Western Australia, aiming for a maiden resource estimate by mid-2026. The program targets the Lightning and Wildflower prospects with over 6,800 metres planned.

InhaleRx Limited has completed the final tranche of its share placement, raising $600,000 to support its clinical-stage drug development programs targeting pain and mental health.

Terrain Minerals has made significant progress across its gold, lithium, and rare earth projects during the December 2025 quarter, including drilling milestones and a successful $2.76 million capital raise. The company targets a maiden resource at its Lightning gold prospect by mid-2026.

RocketBoots Limited has successfully raised A$7 million through a placement to accelerate its international expansion following a transformative global contract. The capital injection aims to scale its AI-driven loss-prevention platform and convert a robust enterprise pipeline.

TerraCom Limited has announced a partially underwritten renounceable entitlement offer aiming to raise approximately A$60 million to bolster its financial position amid ongoing coal price pressures. Key directors have committed to participate, while substantial shareholder Orbit Marketing stands ready to underwrite a significant portion of any shortfall.

Neurizon Therapeutics has locked in a $44 million funding package to fully support its lead drug NUZ-001 in the HEALEY ALS Platform Trial, marking a critical step toward potential regulatory approval and broader neurodegenerative applications.

MRG Metals has raised $0.73 million through a placement to advance its rare earth and heavy mineral sands projects in Mozambique and South Africa, including a strategic acquisition and mining license progression.

Blue Star Helium Limited has raised up to A$8.2 million through a placement and rights issue to fund production scale-up and further drilling at its Galactica helium project in North America.

Tartana Minerals has received $1 million from a new investor as part of a $1.275 million placement, setting the stage for debt reduction and upcoming shareholder decisions.